三拗片联合抗菌药物对慢性阻塞性肺疾病并发肺部细菌感染的影响  

Effect of San'ao Tablets and Antibiotics on Pulmonary Bacterial Infections in Patients with Chronic Obstructive Pulmonary Disease

作　　者：马小芬 韩小莹[2] 马丽丽 梅建新 张学平[1] MA Xiao-Fen;HAN Xiao-Ying;MA Li-Li;MEI Jian-Xin;ZHANG Xue-Ping(Department of Respiratory and Critical Care Medicine,Binzhou Central Hospital,Binzhou 251700,China;Respiratory Endoscopy Room,Binzhou Central Hospital,Binzhou251700,China)

机构地区：[1]滨州市中心医院呼吸与危重症医学科,山东滨州251700 [2]滨州市中心医院呼吸内镜室,山东滨州1251700

出　　处：《中国药物经济学》2025年第3期60-63,68,共5页China Journal of Pharmaceutical Economics

摘　　要：目的探讨慢性阻塞性肺疾病(COPD)并发肺部细菌感染患者采用三拗片联合抗菌药物治疗的效果。方法选取2022年1—12月滨州市中心医院收治的140例COPD并发肺部细菌感染患者,按随机数字表法分为观察组(n=70)与对照组(n=70)。两组均接受常规对症治疗,同时对照组给予左氧氟沙星治疗,观察组采用三拗片联合左氧氟沙星治疗。比较两组患者临床疗效、症状改善时间、肺功能、炎症因子水平、不良反应。结果观察组治疗总有效率97.14%(68/70)较对照组85.71%(60/70)更高(P<0.05);观察组气促、胸闷、咳痰、咳嗽改善时间及退热时间较对照组更短(P<0.05);治疗后两组最大呼气流量(MEF)、最大呼气峰值流速(PEF)、用力肺活量(FVC)、第一秒钟用力呼气容积(FEV_(1))/FVC升高(P<0.05),且观察组较对照组更高(P<0.05);治疗后两组降钙素原(PCT)、血清淀粉样蛋白A(SAA)、白细胞介素-6(IL-6)水平降低(P<0.05),且观察组较对照组更低(P<0.05);观察组不良反应发生率2.86%(2/70)较对照组的12.86%(9/70)更低(P<0.05)。结论三拗片联合抗菌药物应用于COPD并发肺部细菌感染患者治疗中,能够提高临床疗效及肺功能,促进症状缓解,降低炎症因子水平,减少不良反应发生。Objective To explore the effect of San'ao tablets and antibiotics in patients with chronic obstructive pulmonary disease(COPD)and pulmonary bacterial infections.Methods A total of 140 patients with COPD complicated with pulmonary bacterial infection admitted to Binzhou Central Hospital from January to December 2022 were selected and divided into observation group(n=70)and control group(n=70)according to random number table method.Both groups received conventional symptomatic treatment,while the control group was treated with levofloxacin,and the observation group was treated with Sanao tablet combined with levofloxacin.The clinical efficacy,symptom improvement time,lung function,inflammatory factor level and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.14%(68/70)higher than that of the control group 85.71%(60/70)(P<0.05).The improvement time of shortness of breath,chest tightness,sputum,cough and fever in the observation group were shorter than those in the control group(P<0.05).After treatment,the maximum expiratory flow rate(MEF),maximum peak expiratory flow rate(PEF),forced vital capacity(FVC)and forced expiratory volume(FEV_(1))/FVC in the first second of both groups were increased(P<0.05),and the observation group was higher than the control group(P<0.05).After treatment,the levels of procalcitonin(PCT),serum amyloid A(SAA)and interleukin-6(IL-6)in both groups were decreased(P<0.05),and the levels in observation group were lower than those in control group(P<0.05).The incidence of adverse reactions in observation group was 2.86%(2/70)lower than that in control group 12.86%(9/70)(P<0.05).Conclusion Sanao tablets combined with antibiotics in the treatment of COPD patients with pulmonary bacterial infection can improve clinical efficacy and lung function,promote symptom relief,reduce the level of inflammatory factors,and reduce the occurrence of adverse reactions.

关 键 词：三拗片 抗菌药物 慢性阻塞性肺疾病 肺部细菌感染 

分 类 号：R563.3[医药卫生—呼吸系统] R974[医药卫生—内科学]